Illumina Inc. (NASDAQ: ILMN) today announced an expanded clinical oncology portfolio, unlocking the next new solutions to advance precision oncology and improve the standard of care. The company's broad range of clinical offerings will accelerate access to precision oncology for more patients with cancer. Illumina tumor profiling and in vitro diagnostic (IVD) solutions will be on display at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.67 billion for the second quarter ended April 30, 2025, representing growth of 6.0% reported and up 5.3% core(1) compared with the second quarter of 2024.

Introduction Point-of-care testing (POCT) is a subfield of in vitro diagnostics (IVD), where portable analytical instruments and supporting reagents are used to obtain test results quickly at the sampling site. ..

Caris Life Sciences ® (“Caris”), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Caris has applied to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol “CAI.”

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) for TruSightTM Oncology (TSO) Comprehensive for Class III/IV Medical Device (Specially Controlled Medical Device) in Japan. As genomic insights continue to drive breakthroughs in cancer treatment, the test is designed to make precision oncology more accessible to oncologists and patients.

Livzon Pharmaceutical Group said it will take a controlling stake in Vietnam’s Imexpharm for VND5.73 trillion (USD220.7 million) so as to further expand the Chinese drugmaker’s business overseas.

Original from: Roche Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a strategic collaboration with Broad Clinical Labs to develop and pilot groundbreaking applications using Roche’s recently unveile..

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR (dPCR) assays and customized molecular testing solutions for oncology and other disease areas, to expand the availability of dPCR assays for oncology research applications.

OncoSwab, a biotechnology company focused on early detection of cancer through non-invasive molecular testing, today announced it has entered into a collaboration agreement with Mayo Clinic. The agreement provides OncoSwab with access to clinical research expertise and know-how to support the development of its nasal swab-based diagnostic platform.

Original from: Medtronic Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2025 (FY25), which ended April ..

Biostate AI said Tuesday that it has raised $12 million in a Series A financing round.

1) Further Popularization of Automated and Intelligent Diagnostic Equipment Currently, most level-Ⅲ hospitals and some level-Ⅱ hospitals in China are equipped with automated and intelligent diagnostic devices...

Roche Diagnostics Breaks Ground on New Investment Project in Suzhou On May 13, Roche Diagnostics Products (Suzhou) Co., Ltd. (“Roche Diagnostics Suzhou”) held a groundbreaking ceremony fo..

Biostate AI said Tuesday that it has raised $12 million in a Series A financing round.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to develop a companion diagnostic (CDx) test with Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers. Tempus completed confirmatory testing in Verastem’s Phase 2 RAMP-201 clinical trial, which evaluated the combination of avutometinib and defactinib to treat recurrent low-grade serous ovarian cancer (LGSOC) and was the basis of the recent U.S. Food and Drug Administration’s (FDA) accelerated approval of the combination in KRAS-mutated recurrent LGSOC.